Drugs giant GlaxoSmithKline is to increase its stake in US biopharmaceutical company Theravance.
Theravance will issue 10m shares to Glaxo at $21.2887 per share, meaning the UK company will spend $212.9m to up its stake in Theravance from 18.3% to 26.8%.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The two companies have been collaborating since 2002 on drugs development, including work on Relovair, seen as a successor to Glaxo's top-selling inhaled lung treatment Advair.
Relovair has now completed its Phase III development and Glaxo intends to submit regulatory applications for chronic obstructive pulmonary disease in the US and Europe in mid-2012.
For the treatment of asthma using Relovair, Glaxo also plans to submit an application in Europe in mid-2012 and will continue discussions with the US Food and Drug Administraton on the regulatory requirements for a US asthma indication.
NR/JH
-
FCA car finance compensation: £700 each expected for 14 million driversEligible motorists could begin getting a payout from next year under the financial watchdog’s planned car finance compensation scheme
-
Reeves warned against property tax shake-up – 3 ways it could backfire on first-time buyersRachel Reeves reportedly has her eye on high-end property taxes in the upcoming Budget, but there are concerns a shake-up could unintentionally hamper those trying to get on the housing ladder
